Loading…
Low microRNA-139 expression associates with poor prognosis in patients with tumors: A meta-analysis
microRNA-139 (miR-139) is dysregulated in various types of tumors and plays a key role in carcinogenesis. miR-139 may be used as a diagnostic and prognostic biomarker of cancers. However, the data from the literature are not consistent. The present study aimed to verify the prognostic and diagnostic...
Saved in:
| Published in: | Hepatobiliary & pancreatic diseases international 2019-08, Vol.18 (4), p.321-331 |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c392t-a4dd74b64e4b595443c10ebf753e82523196016e9acb7ec3aea722067fa96bbd3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c392t-a4dd74b64e4b595443c10ebf753e82523196016e9acb7ec3aea722067fa96bbd3 |
| container_end_page | 331 |
| container_issue | 4 |
| container_start_page | 321 |
| container_title | Hepatobiliary & pancreatic diseases international |
| container_volume | 18 |
| creator | Chen, Jian-An Yu, Yan Xue, Chen Chen, Xiao-Long Cui, Guang-Ying Li, Juan Li, Kong-Fei Ren, Zhi-Gang Sun, Ran-Ran |
| description | microRNA-139 (miR-139) is dysregulated in various types of tumors and plays a key role in carcinogenesis. miR-139 may be used as a diagnostic and prognostic biomarker of cancers. However, the data from the literature are not consistent. The present study aimed to verify the prognostic and diagnostic values of miR-139 in solid tumors.
PubMed, Web of Science and Embase databases were searched and publications from January 2011 to August 2017 were included. We used Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) database to further validate this meta-analysis.
Eight individual studies from seven articles were included. Pooled analyses showed that low miR-139 expression was related to worse overall survival (OS) [hazard ratio (HR) = 2.27; 95% confidence intervals (CI): 1.74–2.95; P |
| doi_str_mv | 10.1016/j.hbpd.2018.09.016 |
| format | article |
| fullrecord | <record><control><sourceid>wanfang_jour_proqu</sourceid><recordid>TN_cdi_wanfang_journals_gjgdybzz_z201904006</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><wanfj_id>gjgdybzz_z201904006</wanfj_id><els_id>S1499387218302066</els_id><sourcerecordid>gjgdybzz_z201904006</sourcerecordid><originalsourceid>FETCH-LOGICAL-c392t-a4dd74b64e4b595443c10ebf753e82523196016e9acb7ec3aea722067fa96bbd3</originalsourceid><addsrcrecordid>eNp9kEuv0zAQRrMAcS8X_gAL5CUSSvArDyM21RUvqQIJwdqynUmvoyYOHofS_npctbBkMRppfOaT5xTFC0YrRlnzZqwe7NJXnLKuoqrKo0fFLZNKlaJr-U3xFHGklHdd3TwpbgTliipFbwu3DQcyeRfDty-bkglF4PcSAdGHmRjE4LxJgOTg0wNZQohkiWE3B_RI_EwWkzzM6fqe1ilEfEs2ZIJkSjOb_TGDz4rHg9kjPL_2u-LHh_ff7z-V268fP99vtqUTiqfSyL5vpW0kSFurWkrhGAU7tLWAjtdcMNXku0AZZ1twwoBpOadNOxjVWNuLu-L1Jfdg5sHMOz2GNeY_oN6Nu_5oTyd9yoIUlZQ2mX51ofNBP1fApCePDvZ7M0NYUXPGmk62uTLKL2jWhBhh0Ev0k4lHzag-69ejPuvXZ_2aKp1HeenlNX-1E_T_Vv66z8C7CwDZyS8PUaPLMh30PoJLug_-f_l_ADXmmOs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2116847684</pqid></control><display><type>article</type><title>Low microRNA-139 expression associates with poor prognosis in patients with tumors: A meta-analysis</title><source>Freely Accessible Journals</source><source>ScienceDirect Journals</source><creator>Chen, Jian-An ; Yu, Yan ; Xue, Chen ; Chen, Xiao-Long ; Cui, Guang-Ying ; Li, Juan ; Li, Kong-Fei ; Ren, Zhi-Gang ; Sun, Ran-Ran</creator><creatorcontrib>Chen, Jian-An ; Yu, Yan ; Xue, Chen ; Chen, Xiao-Long ; Cui, Guang-Ying ; Li, Juan ; Li, Kong-Fei ; Ren, Zhi-Gang ; Sun, Ran-Ran</creatorcontrib><description>microRNA-139 (miR-139) is dysregulated in various types of tumors and plays a key role in carcinogenesis. miR-139 may be used as a diagnostic and prognostic biomarker of cancers. However, the data from the literature are not consistent. The present study aimed to verify the prognostic and diagnostic values of miR-139 in solid tumors.
PubMed, Web of Science and Embase databases were searched and publications from January 2011 to August 2017 were included. We used Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) database to further validate this meta-analysis.
Eight individual studies from seven articles were included. Pooled analyses showed that low miR-139 expression was related to worse overall survival (OS) [hazard ratio (HR) = 2.27; 95% confidence intervals (CI): 1.74–2.95; P < 0.001] in solid tumors, including hepatocellular carcinoma (HCC) and glioblastoma multiforme (GBM), consisting with the results of TCGA. However, our results of CRC showed that low miR-139 expression was associated with poor OS which was contradictory with the results in TCGA database and need larger samples to validate the phenomenon; whereas for CRC patients, high miR-139 expression predicted poor RFS, which was in good accordance with TCGA results. The results of 27 microarrays from GEO database showed that miR-139 expression levels were lower in tumor tissues compared to adjacent non-tumor tissues or healthy tissues. Decreased miR-139 expression was also significantly correlated with poor differentiation grade (OR = 3.57; 95% CI: 1.44–8.85; P = 0.006). However, the combined data indicated that no associations between miR-139 expression and the following parameters such as age (pooled OR = 1.50; 95% CI: 0.69–3.24; P = 0.304), gender (pooled OR = 0.92; 95% CI: 0.56–1.51; P = 0.738), tumor size (pooled OR = 1.51; 95% CI: 0.69–3.31; P = 0.298), late tumor-node-metastasis stage (pooled OR = 1.63; 95% CI: 0.99–2.68; P = 0.057) and lymph-node-metastasis (pooled OR = 0.66; 95% CI: 0.34–1.28; P = 0.222).
Low miR-139 expression was related to poor prognosis in HCC and GBM, which could be regarded as a potential prognostic biomarker. However, its precise functional role in CRC still need to be further investigated through larger samples and multicenter studies.</description><identifier>ISSN: 1499-3872</identifier><identifier>DOI: 10.1016/j.hbpd.2018.09.016</identifier><identifier>PMID: 30290990</identifier><language>eng</language><publisher>Singapore: Elsevier B.V</publisher><subject>Aged ; Biomarkers, Tumor - genetics ; Databases, Genetic ; Down-Regulation ; Female ; Gene Expression Regulation, Neoplastic ; GEO database ; Humans ; Male ; microRNA-139 ; microRNAs ; MicroRNAs - genetics ; Middle Aged ; Neoplasms - genetics ; Neoplasms - mortality ; Neoplasms - pathology ; Neoplasms - therapy ; Prognosis ; Risk Factors ; TCGA dataset</subject><ispartof>Hepatobiliary & pancreatic diseases international, 2019-08, Vol.18 (4), p.321-331</ispartof><rights>2018 First Affiliated Hospital, Zhejiang University School of Medicine in China</rights><rights>Copyright © 2018 First Affiliated Hospital, Zhejiang University School of Medicine in China. Published by Elsevier B.V. All rights reserved.</rights><rights>Copyright © Wanfang Data Co. Ltd. All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c392t-a4dd74b64e4b595443c10ebf753e82523196016e9acb7ec3aea722067fa96bbd3</citedby><cites>FETCH-LOGICAL-c392t-a4dd74b64e4b595443c10ebf753e82523196016e9acb7ec3aea722067fa96bbd3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Uhttp://www.wanfangdata.com.cn/images/PeriodicalImages/gjgdybzz-z/gjgdybzz-z.jpg</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30290990$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chen, Jian-An</creatorcontrib><creatorcontrib>Yu, Yan</creatorcontrib><creatorcontrib>Xue, Chen</creatorcontrib><creatorcontrib>Chen, Xiao-Long</creatorcontrib><creatorcontrib>Cui, Guang-Ying</creatorcontrib><creatorcontrib>Li, Juan</creatorcontrib><creatorcontrib>Li, Kong-Fei</creatorcontrib><creatorcontrib>Ren, Zhi-Gang</creatorcontrib><creatorcontrib>Sun, Ran-Ran</creatorcontrib><title>Low microRNA-139 expression associates with poor prognosis in patients with tumors: A meta-analysis</title><title>Hepatobiliary & pancreatic diseases international</title><addtitle>Hepatobiliary Pancreat Dis Int</addtitle><description>microRNA-139 (miR-139) is dysregulated in various types of tumors and plays a key role in carcinogenesis. miR-139 may be used as a diagnostic and prognostic biomarker of cancers. However, the data from the literature are not consistent. The present study aimed to verify the prognostic and diagnostic values of miR-139 in solid tumors.
PubMed, Web of Science and Embase databases were searched and publications from January 2011 to August 2017 were included. We used Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) database to further validate this meta-analysis.
Eight individual studies from seven articles were included. Pooled analyses showed that low miR-139 expression was related to worse overall survival (OS) [hazard ratio (HR) = 2.27; 95% confidence intervals (CI): 1.74–2.95; P < 0.001] in solid tumors, including hepatocellular carcinoma (HCC) and glioblastoma multiforme (GBM), consisting with the results of TCGA. However, our results of CRC showed that low miR-139 expression was associated with poor OS which was contradictory with the results in TCGA database and need larger samples to validate the phenomenon; whereas for CRC patients, high miR-139 expression predicted poor RFS, which was in good accordance with TCGA results. The results of 27 microarrays from GEO database showed that miR-139 expression levels were lower in tumor tissues compared to adjacent non-tumor tissues or healthy tissues. Decreased miR-139 expression was also significantly correlated with poor differentiation grade (OR = 3.57; 95% CI: 1.44–8.85; P = 0.006). However, the combined data indicated that no associations between miR-139 expression and the following parameters such as age (pooled OR = 1.50; 95% CI: 0.69–3.24; P = 0.304), gender (pooled OR = 0.92; 95% CI: 0.56–1.51; P = 0.738), tumor size (pooled OR = 1.51; 95% CI: 0.69–3.31; P = 0.298), late tumor-node-metastasis stage (pooled OR = 1.63; 95% CI: 0.99–2.68; P = 0.057) and lymph-node-metastasis (pooled OR = 0.66; 95% CI: 0.34–1.28; P = 0.222).
Low miR-139 expression was related to poor prognosis in HCC and GBM, which could be regarded as a potential prognostic biomarker. However, its precise functional role in CRC still need to be further investigated through larger samples and multicenter studies.</description><subject>Aged</subject><subject>Biomarkers, Tumor - genetics</subject><subject>Databases, Genetic</subject><subject>Down-Regulation</subject><subject>Female</subject><subject>Gene Expression Regulation, Neoplastic</subject><subject>GEO database</subject><subject>Humans</subject><subject>Male</subject><subject>microRNA-139</subject><subject>microRNAs</subject><subject>MicroRNAs - genetics</subject><subject>Middle Aged</subject><subject>Neoplasms - genetics</subject><subject>Neoplasms - mortality</subject><subject>Neoplasms - pathology</subject><subject>Neoplasms - therapy</subject><subject>Prognosis</subject><subject>Risk Factors</subject><subject>TCGA dataset</subject><issn>1499-3872</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp9kEuv0zAQRrMAcS8X_gAL5CUSSvArDyM21RUvqQIJwdqynUmvoyYOHofS_npctbBkMRppfOaT5xTFC0YrRlnzZqwe7NJXnLKuoqrKo0fFLZNKlaJr-U3xFHGklHdd3TwpbgTliipFbwu3DQcyeRfDty-bkglF4PcSAdGHmRjE4LxJgOTg0wNZQohkiWE3B_RI_EwWkzzM6fqe1ilEfEs2ZIJkSjOb_TGDz4rHg9kjPL_2u-LHh_ff7z-V268fP99vtqUTiqfSyL5vpW0kSFurWkrhGAU7tLWAjtdcMNXku0AZZ1twwoBpOadNOxjVWNuLu-L1Jfdg5sHMOz2GNeY_oN6Nu_5oTyd9yoIUlZQ2mX51ofNBP1fApCePDvZ7M0NYUXPGmk62uTLKL2jWhBhh0Ev0k4lHzag-69ejPuvXZ_2aKp1HeenlNX-1E_T_Vv66z8C7CwDZyS8PUaPLMh30PoJLug_-f_l_ADXmmOs</recordid><startdate>20190801</startdate><enddate>20190801</enddate><creator>Chen, Jian-An</creator><creator>Yu, Yan</creator><creator>Xue, Chen</creator><creator>Chen, Xiao-Long</creator><creator>Cui, Guang-Ying</creator><creator>Li, Juan</creator><creator>Li, Kong-Fei</creator><creator>Ren, Zhi-Gang</creator><creator>Sun, Ran-Ran</creator><general>Elsevier B.V</general><general>Precision Medicine Center, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China</general><general>Key Laboratory of Clinical Medicine, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China%Department of Hematology, Yinzhou People's Hospital Affiliated to Medical Col ege of Ningbo University, Ningbo 315040, China</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>2B.</scope><scope>4A8</scope><scope>92I</scope><scope>93N</scope><scope>PSX</scope><scope>TCJ</scope></search><sort><creationdate>20190801</creationdate><title>Low microRNA-139 expression associates with poor prognosis in patients with tumors: A meta-analysis</title><author>Chen, Jian-An ; Yu, Yan ; Xue, Chen ; Chen, Xiao-Long ; Cui, Guang-Ying ; Li, Juan ; Li, Kong-Fei ; Ren, Zhi-Gang ; Sun, Ran-Ran</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c392t-a4dd74b64e4b595443c10ebf753e82523196016e9acb7ec3aea722067fa96bbd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Aged</topic><topic>Biomarkers, Tumor - genetics</topic><topic>Databases, Genetic</topic><topic>Down-Regulation</topic><topic>Female</topic><topic>Gene Expression Regulation, Neoplastic</topic><topic>GEO database</topic><topic>Humans</topic><topic>Male</topic><topic>microRNA-139</topic><topic>microRNAs</topic><topic>MicroRNAs - genetics</topic><topic>Middle Aged</topic><topic>Neoplasms - genetics</topic><topic>Neoplasms - mortality</topic><topic>Neoplasms - pathology</topic><topic>Neoplasms - therapy</topic><topic>Prognosis</topic><topic>Risk Factors</topic><topic>TCGA dataset</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chen, Jian-An</creatorcontrib><creatorcontrib>Yu, Yan</creatorcontrib><creatorcontrib>Xue, Chen</creatorcontrib><creatorcontrib>Chen, Xiao-Long</creatorcontrib><creatorcontrib>Cui, Guang-Ying</creatorcontrib><creatorcontrib>Li, Juan</creatorcontrib><creatorcontrib>Li, Kong-Fei</creatorcontrib><creatorcontrib>Ren, Zhi-Gang</creatorcontrib><creatorcontrib>Sun, Ran-Ran</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Wanfang Data Journals - Hong Kong</collection><collection>WANFANG Data Centre</collection><collection>Wanfang Data Journals</collection><collection>万方数据期刊 - 香港版</collection><collection>China Online Journals (COJ)</collection><collection>China Online Journals (COJ)</collection><jtitle>Hepatobiliary & pancreatic diseases international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chen, Jian-An</au><au>Yu, Yan</au><au>Xue, Chen</au><au>Chen, Xiao-Long</au><au>Cui, Guang-Ying</au><au>Li, Juan</au><au>Li, Kong-Fei</au><au>Ren, Zhi-Gang</au><au>Sun, Ran-Ran</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Low microRNA-139 expression associates with poor prognosis in patients with tumors: A meta-analysis</atitle><jtitle>Hepatobiliary & pancreatic diseases international</jtitle><addtitle>Hepatobiliary Pancreat Dis Int</addtitle><date>2019-08-01</date><risdate>2019</risdate><volume>18</volume><issue>4</issue><spage>321</spage><epage>331</epage><pages>321-331</pages><issn>1499-3872</issn><abstract>microRNA-139 (miR-139) is dysregulated in various types of tumors and plays a key role in carcinogenesis. miR-139 may be used as a diagnostic and prognostic biomarker of cancers. However, the data from the literature are not consistent. The present study aimed to verify the prognostic and diagnostic values of miR-139 in solid tumors.
PubMed, Web of Science and Embase databases were searched and publications from January 2011 to August 2017 were included. We used Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) database to further validate this meta-analysis.
Eight individual studies from seven articles were included. Pooled analyses showed that low miR-139 expression was related to worse overall survival (OS) [hazard ratio (HR) = 2.27; 95% confidence intervals (CI): 1.74–2.95; P < 0.001] in solid tumors, including hepatocellular carcinoma (HCC) and glioblastoma multiforme (GBM), consisting with the results of TCGA. However, our results of CRC showed that low miR-139 expression was associated with poor OS which was contradictory with the results in TCGA database and need larger samples to validate the phenomenon; whereas for CRC patients, high miR-139 expression predicted poor RFS, which was in good accordance with TCGA results. The results of 27 microarrays from GEO database showed that miR-139 expression levels were lower in tumor tissues compared to adjacent non-tumor tissues or healthy tissues. Decreased miR-139 expression was also significantly correlated with poor differentiation grade (OR = 3.57; 95% CI: 1.44–8.85; P = 0.006). However, the combined data indicated that no associations between miR-139 expression and the following parameters such as age (pooled OR = 1.50; 95% CI: 0.69–3.24; P = 0.304), gender (pooled OR = 0.92; 95% CI: 0.56–1.51; P = 0.738), tumor size (pooled OR = 1.51; 95% CI: 0.69–3.31; P = 0.298), late tumor-node-metastasis stage (pooled OR = 1.63; 95% CI: 0.99–2.68; P = 0.057) and lymph-node-metastasis (pooled OR = 0.66; 95% CI: 0.34–1.28; P = 0.222).
Low miR-139 expression was related to poor prognosis in HCC and GBM, which could be regarded as a potential prognostic biomarker. However, its precise functional role in CRC still need to be further investigated through larger samples and multicenter studies.</abstract><cop>Singapore</cop><pub>Elsevier B.V</pub><pmid>30290990</pmid><doi>10.1016/j.hbpd.2018.09.016</doi><tpages>11</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1499-3872 |
| ispartof | Hepatobiliary & pancreatic diseases international, 2019-08, Vol.18 (4), p.321-331 |
| issn | 1499-3872 |
| language | eng |
| recordid | cdi_wanfang_journals_gjgdybzz_z201904006 |
| source | Freely Accessible Journals; ScienceDirect Journals |
| subjects | Aged Biomarkers, Tumor - genetics Databases, Genetic Down-Regulation Female Gene Expression Regulation, Neoplastic GEO database Humans Male microRNA-139 microRNAs MicroRNAs - genetics Middle Aged Neoplasms - genetics Neoplasms - mortality Neoplasms - pathology Neoplasms - therapy Prognosis Risk Factors TCGA dataset |
| title | Low microRNA-139 expression associates with poor prognosis in patients with tumors: A meta-analysis |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-30T19%3A37%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wanfang_jour_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Low%20microRNA-139%20expression%20associates%20with%20poor%20prognosis%20in%20patients%20with%20tumors:%20A%20meta-analysis&rft.jtitle=Hepatobiliary%20&%20pancreatic%20diseases%20international&rft.au=Chen,%20Jian-An&rft.date=2019-08-01&rft.volume=18&rft.issue=4&rft.spage=321&rft.epage=331&rft.pages=321-331&rft.issn=1499-3872&rft_id=info:doi/10.1016/j.hbpd.2018.09.016&rft_dat=%3Cwanfang_jour_proqu%3Egjgdybzz_z201904006%3C/wanfang_jour_proqu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c392t-a4dd74b64e4b595443c10ebf753e82523196016e9acb7ec3aea722067fa96bbd3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2116847684&rft_id=info:pmid/30290990&rft_wanfj_id=gjgdybzz_z201904006&rfr_iscdi=true |